Who are Nipent's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nipent, ADX-324 Dose Level 2, Adezunap (AP707), CEDAZURIDINE, Inqovi, Dacogen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pentostatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Nipent — Competitive Intelligence Brief

Nipent (PENTOSTATIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside Metabolic Inhibitor [EPC]. Area: Oncology.

marketed Nucleoside Metabolic Inhibitor [EPC] Adenosine deaminase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Nipent (PENTOSTATIN) — Hospira Inc.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nipent TARGET	PENTOSTATIN	Hospira Inc	marketed	Nucleoside Metabolic Inhibitor [EPC]	Adenosine deaminase	1991-01-01
Nipent	Pentostatin	Pfizer Inc.	marketed	Nucleoside Metabolic Inhibitor [EPC]	Adenosine deaminase (ADA)
ADX-324 Dose Level 2	ADX-324 Dose Level 2	ADARx Pharmaceuticals, Inc.	phase 3	ADAR1 inhibitor	ADAR1 (Adenosine Deaminase Acting on RNA 1)
Adezunap (AP707)	Adezunap (AP707)	Apurano Pharmaceuticals GmbH	phase 3	Adenosine deaminase inhibitor	Adenosine deaminase (ADA)
CEDAZURIDINE	CEDAZURIDINE		marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA methyltransferase	2020-01-01
Inqovi	Inqovi	Otsuka	marketed	Nucleoside Metabolic Inhibitor [EPC]	Cytidine deaminase	2020-01-01
Dacogen	decitabine	Sun Pharma	marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA (cytosine-5)-methyltransferase 1	2006-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-10-16 — Inqovi · 8618075 · US
2028-10-16 — Inqovi · 9567363 · US
2030-08-22 — Inqovi · 8268800 · US

Sponsor landscape (Nucleoside Metabolic Inhibitor [EPC] class)

· 4 drugs in this class
Bristol-Myers Squibb · 1 drug in this class
Cheplapharm · 1 drug in this class
Extrovis · 1 drug in this class
Hospira Inc · 1 drug in this class
Novartis · 1 drug in this class
Otsuka · 1 drug in this class
Pfizer Inc. · 1 drug in this class
Sanofi · 1 drug in this class
Sun Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nipent — Competitive Intelligence Brief. https://druglandscape.com/ci/pentostatin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab